Medical College, Pingdingshan University, Pingdingshan 467000, China.
Beijing Key Laboratory of Traditional Chinese Medicine Basic Research on Prevention and Treatment for Major Diseases, Experimental Research Center, China.
J Tradit Chin Med. 2020 Dec;40(6):956-964. doi: 10.19852/j.cnki.jtcm.2020.06.007.
To investigate the efficacy of Cyclocarya paliurus (C. paliurus) polysaccharides on stre- ptozotocin-induced diabetic nephropathy in rats.
Rats were divided into 6 groups, including group of normal control, group of diabetic control, group of metformin treatment, low-dose group of C. paliurus polysaccharides treatment, middle-dose group of C. paliurus polysaccharides treatment and high-dose group of C. paliurus polysaccharides treatment. Histological analysis of kidney was analyzed using hematoxilin and eosin. Levels of blood glucose, creatinine, urea, uric acid were determined by spectrophotometry. Anti-oxidative enzymes were measured by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). Advanced glycation end products (AGEs) and transforming growth factor-β1 (TGF-β1) level was measured by ELISA.
Abnormal changes were observed in the group of diabetic control characterized by atrophy of the renal glomeruli with hypercellularity, congestion of glomerular tufts, dilation of the renal spaces, and degeneration of renal tubule. Compared with that of normal group, blood glucose, creatinine, urea, uric acid level was significantly increased in the group of diabetic control. Superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase level was significantly decreased, but AGEs and TGF-β1 level was significantly increased. By contrast, administration of C. paliurus polysaccharides and metformin could reverse the above-mentioned results of the group of diabetic control, especially in the high-dose group of C. paliurus polysaccharides.
Our findings suggest that C. paliurus polysaccharides may play a protecting role for nephropathy of diabetic rats by lowering glucose, creatinine, urea, uric acid level, enhancing the antioxidative ability, and reducing AGEs and TGF-β1 expression.
研究青钱柳多糖对链脲佐菌素诱导的糖尿病肾病大鼠的疗效。
将大鼠分为 6 组,包括正常对照组、糖尿病对照组、二甲双胍治疗组、低剂量青钱柳多糖治疗组、中剂量青钱柳多糖治疗组和高剂量青钱柳多糖治疗组。采用苏木精-伊红染色法对肾脏进行组织学分析。采用分光光度法测定血糖、肌酐、尿素、尿酸水平。实时聚合酶链反应(PCR)和酶联免疫吸附试验(ELISA)测定抗氧化酶。采用 ELISA 法测定晚期糖基化终产物(AGEs)和转化生长因子-β1(TGF-β1)水平。
糖尿病对照组的肾小球萎缩伴细胞增生、肾小球丛充血、肾间质扩张、肾小管变性等异常变化。与正常组相比,糖尿病对照组的血糖、肌酐、尿素、尿酸水平显著升高。超氧化物歧化酶、过氧化氢酶、谷胱甘肽过氧化物酶、谷胱甘肽还原酶水平显著降低,而 AGEs 和 TGF-β1 水平显著升高。相比之下,青钱柳多糖和二甲双胍的给药可以逆转糖尿病对照组的上述结果,尤其是在高剂量青钱柳多糖组。
我们的研究结果表明,青钱柳多糖可能通过降低血糖、肌酐、尿素、尿酸水平,增强抗氧化能力,降低 AGEs 和 TGF-β1 表达,对糖尿病大鼠的肾病发挥保护作用。